Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

<p>Patient and physician preferences for attributes of biologic medications for severe asthma</p>
Heather L. Gelhorn, Zaneta Balantac, Christopher S. Ambrose, et al.
Patient Preference and Adherence (2019) Vol. Volume 13, pp. 1253-1268
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials
Philippe Gevaert, Martin Desrosiers, Marjolein Cornet, et al.
The Lancet (2025)
Closed Access | Times Cited: 2
Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review
Anja St Clair-Jones, Francesca Prignano, João Gonçalves, et al.
Rheumatology and Therapy (2020) Vol. 7, Iss. 4, pp. 741-757
Open Access | Times Cited: 77
Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review
Paul M. Overton, Natalie Shalet, F. Somers, et al.
Patient Preference and Adherence (2021) Vol. Volume 15, pp. 811-834
Open Access | Times Cited: 57
Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume
Mukesh Desai, Amit Kundu, Michiel Hageman, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 17
Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design
J A Stevenson, Rachel Poker, Johanna Schoss, et al.
Advanced Drug Delivery Reviews (2024) Vol. 209, pp. 115322-115322
Closed Access | Times Cited: 7
Patient-reported experiences with refractory or unexplained chronic cough: a qualitative analysis
Vishal Bali, Jonathan Schelfhout, Mandel Sher, et al.
Therapeutic Advances in Respiratory Disease (2024) Vol. 18
Open Access | Times Cited: 6
What matters to people with severe asthma? Exploring add-on asthma medication and outcomes of importance
Vanessa Clark, Peter G. Gibson, Vanessa M. McDonald
ERJ Open Research (2020) Vol. 7, Iss. 1, pp. 00497-2020
Open Access | Times Cited: 36
A Phase 1 study of the long‐acting anti‐IL‐5 monoclonal antibody GSK3511294 in patients with asthma
Dave Singh, Rainard Fuhr, Nicholas Bird, et al.
British Journal of Clinical Pharmacology (2021) Vol. 88, Iss. 2, pp. 702-712
Open Access | Times Cited: 28
Development of an inhaled anti-TSLP therapy for asthma
Paul M. O’Byrne, Reynold A. Panettieri, Christian Taube, et al.
Pulmonary Pharmacology & Therapeutics (2022) Vol. 78, pp. 102184-102184
Open Access | Times Cited: 21
Preference for a Novel Oral Alternative to Parenterally Administered Medications
J. T. Myers, Jacques Van Dam, Mir Imran, et al.
Patient Preference and Adherence (2024) Vol. Volume 18, pp. 1547-1562
Open Access | Times Cited: 4
Pharmacokinetics of Depemokimab Delivered by Safety Syringe Device or Autoinjector in Healthy Adults: A Phase I, Single‐Dose Study
Stein Schalkwijk, Chiara Zecchin, Ayşin Şen, et al.
Clinical Pharmacology in Drug Development (2025)
Open Access
Real-World Biologic Use Patterns in Severe Asthma, 2015–2021: The CLEAR Study
Trung N. Tran, Stephanie Chen, Benjamin Emmanuel, et al.
Pragmatic and Observational Research (2025) Vol. Volume 16, pp. 51-66
Open Access
Perceptions on Home-Administration of Biologics in the Context of Severe Asthma: An International Qualitative Study
Bertine M.J. Flokstra-de Blok, Janwillem Kocks, Hans Wouters, et al.
The Journal of Allergy and Clinical Immunology In Practice (2022) Vol. 10, Iss. 9, pp. 2312-2323.e2
Open Access | Times Cited: 16
Narrative review to capture patients’ perceptions and opinions about non-response and response to biological therapy for severe asthma
Courtney Coleman, Ekaterina Khaleva, Anna Rattu, et al.
European Respiratory Journal (2022) Vol. 61, Iss. 1, pp. 2200837-2200837
Open Access | Times Cited: 15
Real-world severe asthma biologic administration and adherence differs by biologic
Dennis K. Ledford, Weily Soong, Warner Carr, et al.
Annals of Allergy Asthma & Immunology (2023) Vol. 131, Iss. 5, pp. 598-605.e3
Open Access | Times Cited: 8
Physician and patient perspectives on the management of hereditary angioedema: a survey on treatment burden and needs
Marc A. Riedl, Timothy Craig, Aleena Banerji, et al.
Allergy and Asthma Proceedings (2021) Vol. 42, Iss. 3, pp. S17-S25
Closed Access | Times Cited: 19
Real-world reporting rates of administration-site reactions with on-demand treatment of hereditary angioedema attacks
Raffi Tachdjian, Sinisa Savic, Moshe Fridman, et al.
Allergy and Asthma Proceedings (2023) Vol. 45, Iss. 1, pp. 37-43
Closed Access | Times Cited: 8
Bronchial thermoplasty versus mepolizumab: Comparison of outcomes in a severe asthma clinic
David Langton, Joy Sha, Suzy Guo, et al.
Respirology (2020) Vol. 25, Iss. 12, pp. 1243-1249
Open Access | Times Cited: 20
Race and ethnicity, not just insurance, is associated with biologics initiation in asthma and related conditions
Ayobami Akenroye, Christopher Hvisdas, Jessica Stern, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 155, Iss. 3, pp. 1036-1044
Closed Access | Times Cited: 2
Hereditary angioedema patients would prefer newer-generation oral prophylaxis
Daniela Geba, Johan Mohd Sani, Michaela Gascon, et al.
Journal of Drug Assessment (2020) Vol. 10, Iss. 1, pp. 51-56
Open Access | Times Cited: 18
Self-administration of omalizumab: why not? A literature review and expert opinion
Francesco Menzella, Emanuele Ferrari, Silvia Ferrucci, et al.
Expert Opinion on Biological Therapy (2021) Vol. 21, Iss. 4, pp. 499-507
Open Access | Times Cited: 16
Out-of-Pocket Spending for Asthma-Related Care Among Commercially Insured Patients, 2004-2016
Anna D. Sinaiko, Marema Gaye, Ann Chen Wu, et al.
The Journal of Allergy and Clinical Immunology In Practice (2021) Vol. 9, Iss. 12, pp. 4324-4331.e7
Closed Access | Times Cited: 13
Factors leading to discontinuation of biologic therapy in patients with severe asthma
Jared Silver, Michael Bogart, Néstor A. Molfino, et al.
Journal of Asthma (2021) Vol. 59, Iss. 9, pp. 1839-1849
Open Access | Times Cited: 13
Factors Related to Biologic Adherence and Outcomes Among Moderate-to-Severe Asthma Patients
Oyomoare L. Osazuwa‐Peters, Melissa A. Greiner, Amber Oberle, et al.
The Journal of Allergy and Clinical Immunology In Practice (2022) Vol. 10, Iss. 9, pp. 2355-2366
Open Access | Times Cited: 10
Pharmacoequity in Allergy-Immunology: Disparities in Access to Medications for Allergic Diseases and Proposed Solutions in the United States and Globally
Martin Maldonado-Puebla, Ayobami Akenroye, John Busby, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 12, Iss. 2, pp. 272-280
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top